BACKGROUND: Resistance to gemcitabine is a major obstacle in the treatment of advanced pancreatic cancer. Previous exploration of protein kinase inhibitors demonstrated that blocking transforming growth factor-β (TGFβ) signal enhances the efficacy of gemcitabine in pancreatic cancer cells. MATERIALS AND METHODS: We analyzed the cell viability after combinational treatment of TGFβ receptor I (TβRI) inhibitors, SB431542 and SB525334 with gemcitabine in pancreatic cancer cells. In addition, apoptotic cell death and cell migration were measured. RESULTS: Combination with TβRI inhibitors significantly augmented the cytotoxicity of gemcitabine in both parental and gemcitabine resistant pancreatic cancer cells. SB525334 significantly increased apoptotic cell death in gemcitabine-resistant cells. Treatment of SB525334 also affected the AKT signalling pathway, which plays a crucial role in gemcitabine resistance. Migration assay also revealed that blocking TβRI reduces cell migration. CONCLUSION: Chemotherapeutic approaches using SB525334 might enhance the treatment benefit of the gemcitabine-containing regimens in the treatment of pancreatic cancer patients.
BACKGROUND: Resistance to gemcitabine is a major obstacle in the treatment of advanced pancreatic cancer. Previous exploration of protein kinase inhibitors demonstrated that blocking transforming growth factor-β (TGFβ) signal enhances the efficacy of gemcitabine in pancreatic cancer cells. MATERIALS AND METHODS: We analyzed the cell viability after combinational treatment of TGFβ receptor I (TβRI) inhibitors, SB431542 and SB525334 with gemcitabine in pancreatic cancer cells. In addition, apoptotic cell death and cell migration were measured. RESULTS: Combination with TβRI inhibitors significantly augmented the cytotoxicity of gemcitabine in both parental and gemcitabine resistant pancreatic cancer cells. SB525334 significantly increased apoptotic cell death in gemcitabine-resistant cells. Treatment of SB525334 also affected the AKT signalling pathway, which plays a crucial role in gemcitabine resistance. Migration assay also revealed that blocking TβRI reduces cell migration. CONCLUSION: Chemotherapeutic approaches using SB525334 might enhance the treatment benefit of the gemcitabine-containing regimens in the treatment of pancreatic cancerpatients.
Authors: Jimmy Y C Chow; Makiko Ban; Helen L Wu; Flang Nguyen; Mei Huang; Heekyung Chung; Hui Dong; John M Carethers Journal: Am J Physiol Gastrointest Liver Physiol Date: 2009-11-25 Impact factor: 4.052
Authors: Xiaoxian Li; Michael T Lewis; Jian Huang; Carolina Gutierrez; C Kent Osborne; Meng-Fen Wu; Susan G Hilsenbeck; Anne Pavlick; Xiaomei Zhang; Gary C Chamness; Helen Wong; Jeffrey Rosen; Jenny C Chang Journal: J Natl Cancer Inst Date: 2008-04-29 Impact factor: 13.506
Authors: Davide Melisi; Satoshi Ishiyama; Guido M Sclabas; Jason B Fleming; Qianghua Xia; Giampaolo Tortora; James L Abbruzzese; Paul J Chiao Journal: Mol Cancer Ther Date: 2008-04 Impact factor: 6.261
Authors: Jimmy Y C Chow; Khai T Quach; Betty L Cabrera; Jennifer A Cabral; Stayce E Beck; John M Carethers Journal: Carcinogenesis Date: 2007-07-17 Impact factor: 4.944
Authors: Stephanie H Greco; Lena Tomkötter; Anne-Kristin Vahle; Rae Rokosh; Antonina Avanzi; Syed Kashif Mahmood; Michael Deutsch; Sara Alothman; Dalia Alqunaibit; Atsuo Ochi; Constantinos Zambirinis; Tasnima Mohaimin; Mauricio Rendon; Elliot Levie; Mridul Pansari; Alejandro Torres-Hernandez; Donnele Daley; Rocky Barilla; H Leon Pachter; Daniel Tippens; Hassan Malik; Allal Boutajangout; Thomas Wisniewski; George Miller Journal: PLoS One Date: 2015-07-14 Impact factor: 3.240
Authors: Tiago M A Carvalho; Daria Di Molfetta; Maria Raffaella Greco; Tomas Koltai; Khalid O Alfarouk; Stephan J Reshkin; Rosa A Cardone Journal: Cancers (Basel) Date: 2021-12-06 Impact factor: 6.639
Authors: Amarinder Singh Thind; Bruce Ashford; Dario Strbenac; Jenny Mitchell; Jenny Lee; Simon A Mueller; Elahe Minaei; Jay R Perry; Sydney Ch'ng; N Gopalakrishna Iyer; Jonathan R Clark; Ruta Gupta; Marie Ranson Journal: Front Oncol Date: 2022-08-02 Impact factor: 5.738